Zeng Zhang

Chairman at Beijing Continent Pharmaceutical Co., Ltd.

Health Technology

Profile

Zeng Zhang currently holds the position of Chairman-Supervisory Board at Beijing Continent Pharmaceutical Co., Ltd.
His current job is Chairman-Supervisory Board at the same company.

Zeng Zhang active positions

Companies	Position	Start
Beijing Continent Pharmaceutical Co., Ltd. Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China.	Chairman	-

All active positions of Zeng Zhang

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Zeng Zhang's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Beijing Continent Pharmaceutical Co., Ltd. Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China.	Health Technology